notice received, page-14

Question:

If you were a an angel / cornerstone investor and believed in this product, would you come in at this stage and take a stake in the public company, or sit on the sidelines hoping they go broke and then pick up the IP off the receivers?

Pros and cons on both sides.

An existing biomed, with existing capabilities and supply lines, would prefer the second option, where an venture capitalist would prefer the first.

Either way they've confirmed that any solution will result in dilution, which I suppose is preferable to the terminal alternative.